November 02, 2018
Teva Pharmaceuticals USA is recalling 53,451 bottles of metoprolol succinate extended-release tablets USP, 50 mg, after an out-of-specification dissolution result occurred during routine stability testing. The recall was included in the October 31, 2018, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 100-count bottles (NDC 62037-831-01) manufactured by Actavis Laboratories FL and distributed by Actavis Pharma from lot 1220211M (Exp. 2/19). The product was sent to distributors, wholesalers, and retail chains throughout the United States, including Puerto Rico.
Teva Pharmaceuticals initiated the recall October 19, 2018. At press time, the FDA had not yet issued a recall classification.
Metoprolol succinate is a prescription beta-blocker used to treat chest pain, heart failure, and high blood pressure.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here